Savior Lifetec

Savior Lifetec FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Savior Lifetec (4167.TWO) as of Oct 27, 2026 is -30.57 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 219.28 % — a change of -113.94% (lower).

FCF Conversion

-30.57 %

YoY

-113.94%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Savior Lifetec is 2025 -30.57 % . FCF Conversion Rate (FCF/EBITDA) of Savior Lifetec was 2024 219.28 % . It decreases by -113.94% lower compared to the previous year.

The Savior Lifetec FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
109.72 TWD
Jan 1, 2019
97.31 TWD
Jan 1, 2020
-49.92 TWD
Jan 1, 2021
5,541.55 TWD
Jan 1, 2022
2,656.17 TWD
Jan 1, 2023
1,232.34 TWD
Jan 1, 2024
219.28 TWD
Jan 1, 2025
-30.57 TWD
The Savior Lifetec FCF Conversion history
YEARFCF ConversionYoY
-30.57 %-113.94%
219.28 %-82.21%
1,232.34 %-53.60%
2,656.17 %-52.07%
5,541.55 %-11,201.19%
-49.92 %-151.30%
97.31 %-11.31%
109.72 %-81.06%
579.21 %+680.50%
74.21 %-47.29%
140.78 %+2.80%
136.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

FCF Conversion Rate (FCF/EBITDA) of Savior Lifetec is -30.57 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Savior Lifetec changed from 219.28 % to -30.57 %, representing a -113.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Savior Lifetec with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Savior Lifetec

All Key Metrics — Savior Lifetec